We thank Canpolat et al 1 for their valuable comments regarding our article entitled ''The Association Between Serum Procalcitonin Levels and Severity of Coronary Artery Disease Assessed by SYNTAX Score in Patients With Acute Coronary Syndrome.'' 2 First, patients having acute coronary syndrome (ACS) with stable clinical conditions were included in this study. Patients with cardiac arrest, acute decompensated heart failure, cardiogenic shock, defibrillation due to life-threatening arrhythmia, or serious valvular heart disease, as well as those who developed mechanical complications, were excluded from our study. Patients with active or chronic infection or any inflammatory disorders were also excluded. As Canpolat et al 1 state, these conditions might influence serum procalcitonin levels. This is why we excluded them. As regards an increase in procalcitonin levels for a reason other than ACS, the normal range of serum procalcitonin is 0 to 0.1 ng/mL. Procalcitonin levels <0.5 ng/mL are useful for excluding infection. We also evaluated the patients for complaints possibly related to infection (eg, fever, urinary tract complaints, cough, dyspnea, or raised white blood cell count). If we suspected infection, we referred the patients to the infection disease clinics. We excluded the patients according to the decision regarding infection. However, we could not be entirely sure that we had fully excluded patients with infectious diseases, especially subclinical or atypical infectious conditions, that could raise serum procalcitonin levels. Moreover, because our study had a limited budget, the only other inflammatory marker we were able to study besides procalcitonin was high-sensitive C-reactive protein. This is a limitation of our study.
Second, analyzing the results separately for ST-segment elevation and non-ST-segment elevation ACS patient groups could be an aim for a larger, prospective study. Finally, the literature regarding the relationship between procalcitonin and chronic kidney disease (CKD) is contradictory. Opatrna et al showed that serum procalcitonin levels have a negative correlation with creatinine clearance (r ¼ À.44, P < .05). 3 However, Meisner et al 4 demonstrated that procalcitonin levels did not correlate with renal function. They also reported that the rate of decline in plasma procalcitonin levels following resolution of infection did not differ between patients with severe CKD and patients without renal disease. 4 We excluded patients with severe renal dysfunction as a confounding factor. Therefore, we do not think that the marginally higher creatinine values in the high SYNTAX score group affected the results of our study very much. In addition, in another study, the risk of significant lesion complexity increased progressively with decreasing kidney function and that estimated glomerular filtration rate was a strong predictor of higher SYNTAX score. 4 Our results support those in the literature. 5, 6 Further studies related to predictors such as procalcitonin could provide more clinically useful information.
